VIVALIS : 2013 FINANCIAL CALENDAR VIVALIS SHARES TRANSFERRED TO COMPARTMENT B OF NYSE EURONEXT

VIVALIS : 2013 FINANCIAL CALENDAR VIVALIS SHARES TRANSFERRED TO COMPARTMENT B
                               OF NYSE EURONEXT

                           2013 financial calendar

         VIVALIS SHARES transferred to compartment B of NYSE Euronext

Nantes (France) - 11 janvier 2010 - VIVALIS (NYSE EuroneNantes, Lyon (France)
-15 January 2013- VIVALIS (NYSE Euronext), a biopharmaceutical company, today
announces its schedule for the publication of financial information for 2013.
On December 16, 2012, VIVALIS and INTERCELL announced a proposed merger of
equals with the objective to create VALNEVA, a leading European biotechnology
company in vaccines and antibodies. This merger will create an integrated
company with a greater scale and diversification, strengthened financial
profile and complementary talent and capabilities.

Event                                               Date * **
2012 fourth-quarter and annual revenues             Thursday, 14 February 2013
Shareholders' meeting on VIVALIS-INTERCELL Merger   Early March 2013
to form VALNEVA S.E.
2012 annual results                                 Tuesday, 26 March 2013
2013 first-quarter revenues                         Thursday, 25 April 2013
Annual general meeting                              Wednesday, 19 June 2013

* Subject to modification.
** Press releases are published after market closes

Upon completion of the merger, if approved, a new financial calendar will be
circulated for the financial publications of VALNEVA S.E.

In addition, NYSE Euronext has transfered VIVALIS shares from compartment C of
the Euronext to compartment B of the Euronext. This transfer will be effective
beginning 17 January 2013.
About VIVALIS (www.vivalis.com)

Vivalis (NYSE-Euronext:  VLS) is  a  biopharmaceutical company  that  provides 
innovative  cell-based  solutions  to  the  biotechnology  and  pharmaceutical 
industry for  the  manufacture  of  vaccines  and  recombinant  proteins,  and 
develops monoclonal antibodies  for the prevention  and treatment of  diseases 
with unmet medical  needs. Vivalis'  expertise and  intellectual property  are 
leveraged in two main areas:

1.EB66^® Cell Line

Vivalis offers  research and  commercial licenses  for its  EB66^® cell  line, 
derived from duck  embryonic stem cells,  to pharmaceutical and  biotechnology 
companies for the production of  therapeutic and prophylactic viral  vaccines, 
virosomes, VLPs  and recombinant  proteins, including  monoclonal  antibodies. 
Clinical trials of EB66^® produced vaccines are currently on-going in the  USA 
and Japan  and in  2012 a  vaccine  produced in  EB66® cells  received  market 
approval in Japan for use in animal health.  Through these programs,  Vivalis 
receives an  upfront payment,  clinical stage  milestone payments  along  with 
royalties on licensees' net sales.

a.VIVA|Screen(TM) Human Antibody Discovery Platform

Customized solutions for  the discovery, development  and production of  rare, 
fully human  monoclonal  antibodies  are offered  by  Vivalis.  Through  these 
programs, Vivalis receives payments associated  with the funding of  discovery 
research, an upfront  payment, clinical  stage milestone  payments along  with 
royalties on net sales of licensed antibodies that are commercially  developed 
from the use of the platform.

Based in Nantes and Lyon (France)  and in Toyama (Japan), Vivalis was  founded 
in 1999 by the Group Grimaud  (approx. 1,700 employees), one of the  worldwide 
leaders in  animal genetic  selection. Vivalis  has established  more than  30 
partnerships and licenses  with world leaders  in biopharmaceutical  industry, 
including  Sanofi  Pasteur,  GlaxoSmithKline  Biologicals,  Transgene,  Pfizer 
Animal Health,  Kaketsuken, Kitasato  Daiichi  Sankyo Vaccine,  Merial,  Merck 
Animal Health and SAFC Biosciences. Vivalis is a member of the French ATLANTIC
BIOTHERAPIES and  LYON  BIOPOLE bio-clusters  and  a member  of  the  Japanese 
HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE based in Toyama.

VIVALIS
Listed on Euronext Paris - Compartment C of NYSE Euronext
Reuters: VLS.PA - Bloomberg: VLS FP
Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indexes

This document contains forward-looking statements and comments on the
company's objectives and strategies. No guarantee can be given to any of the
events anticipated by the forward-looking statements contained in this
document, which are subject to inherent risks, including risk factors
described in the company's Document de Référence, changes in economic
conditions, the financial markets or the markets in which the company
operates.

Contacts

VIVALIS                      NewCap
Franck Grimaud, CEO          Financial communications agency
Email: investors@vivalis.com Axelle Vuillermet / Pierre Laurent
                             Tel.: +33 (0) 1 44 71 94 93
                             Email: vivalis@newcap.fr

20130115PR EN

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: VIVALIS via Thomson Reuters ONE
HUG#1670533
 
Press spacebar to pause and continue. Press esc to stop.